Literature DB >> 11265583

Antimycobacterial activity of new quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives.

M A Ortega1, M E Montoya, A Jaso, B Zarranz, I Tirapu, I Aldana, A Monge.   

Abstract

The compounds being reported in this paper have all been evaluated within the TAACF Antituberculosis Screen Program, and some of them have been shown to possess high growth inhibition activity against Mycobacterium tuberculosis and Mycobacterium avium in the run of the first and second level in vitro screenings. The three compounds which have shown a good SI (Selectivity Index) are 2b, 4b and 4d; in addition, 6,7-dimethyl-3-[4-(4'-nitrophenyl)piperazinl-yl]quinoxaline-2-carbonitrilo 1,4-di-N-oxide (4b) is currently being tested within the in vivo antituberculosis screening in view of its very good in vitro activity.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11265583

Source DB:  PubMed          Journal:  Pharmazie        ISSN： 0031-7144            Impact factor:   1.267


  8 in total

1.  E-2-[3-(3,4-dichlorophenyl)-1-oxo-2-propenyl]-3-methylquinoxaline-1,4-dioxide: a lead antitubercular agent which alters mitochondrial respiration in rat liver.

Authors:  Umashankar Das; Swagatika Das; Brian Bandy; Dennis K J Gorecki; Jonathan R Dimmock
Journal:  Eur J Med Chem       Date:  2010-07-24       Impact factor: 6.514

2.  Efficacy of quinoxaline-2-carboxylate 1,4-di-N-oxide derivatives in experimental tuberculosis.

Authors:  Esther Vicente; Raquel Villar; Asunción Burguete; Beatriz Solano; Silvia Pérez-Silanes; Ignacio Aldana; Joseph A Maddry; Anne J Lenaerts; Scott G Franzblau; Sang-Hyun Cho; Antonio Monge; Robert C Goldman
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

3.  In vitro and in vivo antimycobacterial activities of ketone and amide derivatives of quinoxaline 1,4-di-N-oxide.

Authors:  Raquel Villar; Esther Vicente; Beatriz Solano; Silvia Pérez-Silanes; Ignacio Aldana; Joseph A Maddry; Anne J Lenaerts; Scott G Franzblau; Sang-Hyun Cho; Antonio Monge; Robert C Goldman
Journal:  J Antimicrob Chemother       Date:  2008-05-23       Impact factor: 5.790

Review 4.  New small-molecule synthetic antimycobacterials.

Authors:  Lluis Ballell; Robert A Field; Ken Duncan; Robert J Young
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Anti-Mycobacterium tuberculosis Activity of Esters of Quinoxaline 1,4-Di-N-Oxide.

Authors:  Isidro Palos; Julieta Luna-Herrera; Edgar E Lara-Ramírez; Alejandra Loera-Piedra; Emanuel Fernández-Ramírez; Ma Guadalupe Aguilera-Arreola; Alma D Paz-González; Antonio Monge; Baojie Wan; Scott Franzblau; Gildardo Rivera
Journal:  Molecules       Date:  2018-06-15       Impact factor: 4.411

Review 6.  Quinoxaline 1,4-di-N-Oxides: Biological Activities and Mechanisms of Actions.

Authors:  Guyue Cheng; Wei Sa; Chen Cao; Liangliang Guo; Haihong Hao; Zhenli Liu; Xu Wang; Zonghui Yuan
Journal:  Front Pharmacol       Date:  2016-03-21       Impact factor: 5.810

7.  Unexpected reduction of ethyl 3-phenylquinoxaline-2- carboxylate 1,4-di-N-oxide derivatives by amines.

Authors:  Lidia M Lima; Esther Vicente; Beatriz Solano; Silvia Pérez-Silanes; Ignacio Aldana; Antonio Monge
Journal:  Molecules       Date:  2008-01-17       Impact factor: 4.411

8.  Heterocyclic-2-carboxylic acid (3-cyano-1,4-di-N-oxidequinoxalin-2-yl)amide derivatives as hits for the development of neglected disease drugs.

Authors:  Saioa Ancizu; Elsa Moreno; Enrique Torres; Asunción Burguete; Silvia Pérez-Silanes; Diego Benítez; Raquel Villar; Beatriz Solano; Adoración Marín; Ignacio Aldana; Hugo Cerecetto; Mercedes González; Antonio Monge
Journal:  Molecules       Date:  2009-06-22       Impact factor: 4.411
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.